Israele - inglese - Ministry of Health

taro pharmaceutical industries ltd - macrogols; potassium chloride; sodium bicarbonate; sodium chloride - powder for solution - macrogols 315.0 g; potassium chloride 1.1175 g; sodium bicarbonate 4.2840 g; sodium chloride 8.4240 g - mineral salts in combination - mineral salts in combination - bowel cleansing prior to colonoscopy and barium enema x-ray examinations.

Israele - inglese - Ministry of Health

remedix care ltd - olive oil; soya oil - emulsion for infusion - olive oil 80 %; soya oil 20 % - oil - oil - source of lipids during parenteral nutrition in situations where oral or enteral feeding is impossible, insufficient or contra-indicated.

Israele - inglese - Ministry of Health

rafa laboratories ltd - budesonide - capsules - budesonide 3 mg - budesonide - budesonide - acute mild to moderate crohn’s disease with involvement of the ileum (twisted intestine) and/or ascending colon (part of large bowel). collagenous colitis.autoimmune hepatitis.

Israele - inglese - Ministry of Health

tzamal bio-pharma ltd - metformin hydrochloride; pioglitazone as hydrochloride - film coated tablets - metformin hydrochloride 850 mg; pioglitazone as hydrochloride 15 mg - metformin - metformin - competact is indicated as second line treatment of type 2 diabetes mellitus adult patients,particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.after initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in hba1c). in patients who fail to show an adequate response, pioglitazone should be discontinued. in light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.

Israele - inglese - Ministry of Health

taro pharmaceutical industries ltd - calcium carbonate - chewable tablets - calcium carbonate 600 mg - calcium carbonate - calcium carbonate - antacid, calcium deficiency.

Israele - inglese - Ministry of Health

abic marketing ltd, israel - levocarnitine - solution - levocarnitine 30 % - levocarnitine - levocarnitine - systemic and myopathic carnitine deficiency.

Israele - inglese - Ministry of Health

pfizer pharmaceuticals israel ltd - taliglucerase alfa - powder for solution for infusion - taliglucerase alfa 200 u/vial - taliglucerase alfa - taliglucerase alfa - elelyso™ (taliglucerase alfa) for injection is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy (ert) for adults and pediatric patients with a confirmed diagnosis of type 1 gaucher disease

Israele - inglese - Ministry of Health

taro pharmaceutical industries ltd - warfarin sodium - tablets - warfarin sodium 1 mg - warfarin - warfarin - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.

Israele - inglese - Ministry of Health

taro pharmaceutical industries ltd - warfarin sodium - tablets - warfarin sodium 2 mg - warfarin - warfarin - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonar embolism. coumadin is indicated for the prophylaxis and/or treatment of the tromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.

Israele - inglese - Ministry of Health

taro pharmaceutical industries ltd - warfarin sodium - tablets - warfarin sodium 2.5 mg - warfarin - warfarin - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.